Abstract:Background and objective Our objective was to investigate the efficacy and safety of dexa methasone (DEX) implant for the treatment of pseudophakic cystoid macular edema (PCME) in diabetic patients. Study design This was a prospective, non-randomized, interventional case series of 43 participants. Eighteen patients were enrolled in the DEX implant group and 25 were enrolled in an intravitreal triamcinolone acetonide (IVTA) group. Main outcome measures The primary efficacy measurement was the percentage of patients who gained improvements of more than ten letters in best corrected visual acuity (BCVA) during 6 months of follow-up. Other efficacy measurements included change in BCVA, change in central macular thickness (CMT), and number of retreatments. The primary safety evaluation was the percentage of patients with intraocular hypertension and variation in intraocular pressure (IOP) during 6 months of follow-up. Other adverse events, such as conjunctival hemorrhage, eye pain, secondary infection, endophthalmitis, noninfectious inflammation, retinal detachment, and implant migration, were also recorded during follow-up. Results At month 1, we observed that the percentage of patients gaining improvement of more than ten letters was similar in both groups (P=0.625). As patients in the IVTA group were retreated several times, this effect persisted throughout the study (P=0.941 at month 2, P=0.553 at month 3, P=0.856 at month 6). Variations in CMT were noticed at week 1 and reached their maximum at month 1. No significant difference was found between the two groups (P=0.831 at week 1, P=0.783 at month 1). At month 1, the variation in IOP reached its maximum in the DEX implant group and then decreased slightly. However, in the IVTA group, it increased continuously throughout the study. Conjunctival hemorrhage and eye pain were found in both groups, but both were rated as mild in severity, and no significant difference was found (P=0.184, P=0.766, respectively). Conclusion Both IVTA and DEX implants could effectively restore visual function and recover morphological change in diabetic patients with PCME for at least 6 months, but repeated intravitreal injection was required in the IVTA group. DEX implant is well tolerated. We suggest that intravitreal injection of DEX implant is a promising new therapeutic option for diabetic patients with PCME.

INTRAVITREALLY INJECTABLE POLY (D, L-LACTIDE) MICROSPHERES CONTAINING DEXAMETHASONE ACETATE FOR SUSTAINED RELEASE

Sustained Intravitreal Delivery of Dexamethasone Using an Injectable and Biodegradable Thermogel.

Intravitreal Administration of Dexamethasone-Loaded PLGA-TPGS Nanoparticles for the Treatment of Posterior Segment Diseases.

PLA–PCL–PEG–PCL–PLA based micelles for improving the ocular permeability of dexamethasone: development, characterization, and in vitro evaluation

Drug release mechanisms of high-drug-load, melt-extruded dexamethasone intravitreal implants

A study of the dexamethasone sodium phosphate release properties from a periocular capsular drug delivery system

PLGA-PEG-PLGA hydrogel for ocular drug delivery of dexamethasone acetate

Manufacturing dexamethasone intravitreal implants: process control and critical quality attributes

Biodegradable dexamethasone polymer capsule for long-term release

Safety and Efficacy of Dexamethasone Intravitreal Implant for Treatment of Macular Edema Secondary to Retinal Vein Occlusion in Chinese Patients: Randomized, Sham-Controlled, Multicenter Study

Long-term corticosteroid-induced chronic glaucoma model produced by intracameral injection of dexamethasone-loaded PLGA microspheres

Development of puerarin-loaded poly(lactic acid) microspheres for sustained ocular delivery: In vitro / vivo evaluation

Evaluations of Therapeutic Efficacy of Intravitreal Injected Polylactic-Glycolic Acid Microspheres Loaded with Triamcinolone Acetonide on a Rabbit Model of Uveitis

Comparison of Dexamethasone Intravitreal Implant and Intravitreal Triamcinolone Acetonide for the Treatment of Pseudophakic Cystoid Macular Edema in Diabetic Patients

Design and Characterization of Ocular Inserts Loaded with Dexamethasone for the Treatment of Inflammatory Ophthalmic Disease

Injectable Poloxamer Hydrogel Formulations for Intratympanic Delivery of Dexamethasone

Intravitreal Dexamethasone Implants for Refractory Macular Edema in Eyes with Noninfectious Uveitis

In vivo evaluation of a Nano-enabled therapeutic vitreous substitute for the precise delivery of triamcinolone to the posterior segment of the eye

Intravitreal Dexamethasone Implant in Anti-Vascular Endothelial Growth Factor Pretreated Diabetic Macular Edema—A Swiss Cohort Study

Dexamethasone Acetate‐Loaded PLGA Nanospheres Targeting Liver Macrophages

Dexamethasone implant for refractory macular edema secondary to diabetic retinopathy and retinal vein occlusion